Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 110.00M | 234.30M | 156.10M | 148.70M | 231.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 110.00M | 234.30M | 156.10M | 148.70M | 231.10M |
| Cost of Revenue | 84.60M | 106.10M | 82.40M | 94.00M | 99.00M |
| Gross Profit | 25.40M | 128.20M | 73.70M | 54.70M | 132.10M |
| SG&A Expenses | 40.40M | 44.60M | 46.60M | 61.60M | 38.90M |
| Depreciation & Amortization | 10.60M | 17.20M | 16.50M | 16.30M | 16.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 135.90M | 167.90M | 145.50M | 171.30M | 154.40M |
| Operating Income | -25.90M | 66.40M | 10.60M | -22.60M | 76.70M |
| Income Before Tax | -36.40M | -166.30M | 13.40M | -50.70M | 57.60M |
| Income Tax Expenses | -3.70M | 13.90M | 6.60M | 3.90M | 6.40M |
| Earnings from Continuing Operations | -32.70M | -180.20M | 6.80M | -54.60M | 51.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.70M | -180.20M | 6.80M | -54.60M | 51.20M |
| EBIT | -25.90M | 66.40M | 10.60M | -22.60M | 76.70M |
| EBITDA | -9.30M | 89.90M | 33.50M | 2.40M | 99.70M |
| EPS Basic | -0.64 | -3.49 | 0.13 | -1.04 | 0.96 |
| Normalized Basic EPS | -0.25 | 0.68 | 0.16 | 0.15 | 0.67 |
| EPS Diluted | -0.64 | -3.49 | 0.07 | -1.04 | 0.91 |
| Normalized Diluted EPS | -0.25 | 0.68 | 0.15 | 0.15 | 0.63 |
| Average Basic Shares Outstanding | 51.30M | 51.60M | 51.90M | 52.40M | 53.20M |
| Average Diluted Shares Outstanding | 51.30M | 51.60M | 56.50M | 52.40M | 56.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |